Mammary gland (Neoplasia)

LE WE PMID CA

Mammary gland (Neoplasia)

423

Brustdruese (Neubildung)

AIB1

AMP activated protein kinase

Anastrozole

Antineoplastic agents (Novel target ideas)

Aromatase Inhibitor

Arzoxifene ttSERM

ATM

Bisphosphonates

Bone (Metastasis)

BRCA

BRCA1

BRCA2

BRIP1

Bruxism

Calphostin C

Capecitabine

Carcinosarcoma

Cdh1

CHEK2

Chemoprevention

CNS (Metastasis)

Colon and rectum (Neoplasia)

COX2

CYP19A1 Aromatase

DNA (Repair and Toxicology)

Docetaxel

Endocrine disruptor

Epigenetics

Epirubicin

Epithelio mesenchymal transition

Exemestane

Fura2

Growth hormone

Gynecomastia

IGF1

Interleukin24 MDA7

Ixabepilone

KLF

Klf4

KLF5

KLF6

KLF9

Laboratory medicine

Lapatinib

Letrozole

LKB1

Lymph node (Metastasis and sentinel)

Mammary gland (Development)

Mammary gland (Imaging)

Mammary gland (Involution)

Mammary gland (Metastasis)

Mammary gland (MRT)

Mammary gland (Neoplasia)

Mammary gland (Sonography)

Matrix producing carcinoma of the breast

MET

Metformin

Microendoscopy

Mouse mammary tumor virus

MRT (functional fMRT)

Myofibroblastoma

Natural products

NBS1

Neoplasia (Carcinogenesis)

Neoplasia (Dormancy)

Neoplasia (Inherited)

Neoplasia (Invasion and metastasis)

Neoplasia (Oncofetal antigens)

Neoplasia (Oncolytic virus)

Neoplasia (Tumor biology and immunology)

Notch

Osteoporosis

Ovary (Neoplasia)

P53

Paclitaxel

PALB2

PARP

PGRMC1

Preventive surgery

Protein kinase B Akt

Protein kinase C

PTEN MMAC1 TEP1

Rad50

Radiopharmacology

Receptor (EGF)

Receptor (Estrogen)

Receptor (Leptin)

Receptor (Progesterone)

SLC39A6

SNAIL

Stem cell (Neoplasia)

Steroid sulfatase

Tamoxifen

TGF beta

Tpl2 Cot

Transporter (Zinc)

Trastuzumab ttHER2

TRPC1

TRPC6

TRPM7

TRPM8

TRPV6

Twist

UFT

Uterus (Neoplasia)

Vitamin D

Wnt beta Catenin TCF

Zinc

1990 1	Carcinoma of the male breast: a review of 41 cases. [1699287] South Med J 83(10): 1162-7 (1990)
2008 2	Hereditary breast and ovarian cancers. [19074707] Can Fam Physician 54(12): 1691-2 (2008)
2002 3	Radiation treatment for breast cancer. Recent advances. [12113193] Can Fam Physician 48(-): 1065-9 (2002)
2010 4	Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. [20204119] Dtsch Arztebl Int 107(6): 85-91 (2010)
2007 5	Breast cancer (non-metastatic). [19450345] Clin Evid (Online) 2007(): (2007)
2009 6	HER2 breast cancer therapies: a review. [19707416] Biologics 3(): 289-301 (2009)
2008 7	Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. [19707381] Biologics 2(3): 505-15 (2008)
2007 8	Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. [19707333] Biologics 1(3): 229-39 (2007)
2007 9	Trastuzumab in the management of early and advanced stage breast cancer. [19707345] Biologics 1(1): 19-31 (2007)
2008 10	Exemestane in early breast cancer: a review. [19337436] Ther Clin Risk Manag 4(6): 1295-304 (2008)
2008 11	Long-term safety of aromatase inhibitors in the treatment of breast cancer. [18728707] Ther Clin Risk Manag 4(1): 189-204 (2008)
2007 12	A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. [18472989] Ther Clin Risk Manag 3(4): 665-73 (2007)
2009 13	The use of paclitaxel in the management of early stage breast cancer. [19567209] Health Technol Assess 13 Suppl 1(): 15-22 (2009)
2009 14	Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. [19567208] Health Technol Assess 13 Suppl 1(): 7-13 (2009)
2009 15	Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. [19567207] Health Technol Assess 13 Suppl 1(): 1-6 (2009)
2007 16	Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. [17903394] Health Technol Assess 11(40): 1-144 (2007)
2007 17	Hormonal therapies for early breast cancer: systematic review and economic evaluation. [17610808] Health Technol Assess 11(26): iii-iv, ix-xi, 1-134 (2007)
2006 18	Papillary carcinoma in a male breast cyst: a diagnostic challenge. [17002839] Ann R Coll Surg Engl 88(5): W3-5 (2006)
1995 19	Management of ductal carcinoma in situ of the breast. [7598411] Ann R Coll Surg Engl 77(3): 163-7 (1995)
1954 20	Carcinoma of the breast: a review of the treatment. [13149066] Ann R Coll Surg Engl 14(4): 215-46 (1954)
2004 21	Axillary lymph node dissection versus the sentinel lymph node technique in breast cancer. [15213611] Ann Surg 240(1): 7-8 (2004)
1998 22	Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. [9605656] Ann Surg 227(5): 645-51; discussion 651-3 (1998)
1994 23	Current management of carcinoma of the breast. [8053734] Ann Surg 220(2): 121-36 (1994)
1992 24	Current management of male breast cancer. A review of 104 cases. [1319699] Ann Surg 215(5): 451-7; discussion 457-9 (1992)
1987 25	Adenoid cystic carcinoma of the breast. Data from the Connecticut Tumor Registry and a review of the literature. [3030200] Ann Surg 205(3): 295-301 (1987)
1985 26	Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy. [3977455] Ann Surg 201(4): 527-32 (1985)
1964 27	PAGET'S DISEASE OF THE MALE BREAST: A CASE REPORT AND A REVIEW OF THE LITERATURE. [14119196] Ann Surg 159(-): 305-9 (1964)
1951 28	The rationale of radical mastectomy; a review. [14819967] Ann Surg 133(3): 330-43 (1951)
2009 29	Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients. [19356240] BMC Cancer 9(): 108 (2009)
2006 30	Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. [17116247] BMC Cancer 6(): 269 (2006)
2006 31	Evidence-based risk factors for seroma formation in breast surgery. [16684859] Jpn J Clin Oncol 36(4): 197-206 (2006)
2010 32	Chemotherapy for breast cancer (Review). [20878101] Oncol Rep 24(5): 1121-31 (2010)
2010 33	Male breast cancer: risk factors, diagnosis, and management (Review). [20878100] Oncol Rep 24(5): 1115-20 (2010)
2008 34	Clinical characteristics of small cell carcinoma of the breast. [18357385] Oncol Rep 19(4): 981-5 (2008)
2009 35	Optimal use of taxanes in metastatic breast cancer. [19526080] Curr Oncol 16(3): 8-20 (2009)
2004 36	Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. [15335458] Clin Breast Cancer 5(3): 235-8 (2004)
2002 37	Bisphosphonates: biological response modifiers in breast cancer. [12196279] Clin Breast Cancer 3(3): 206-16; discussion 217-8 (2002)
2001 38	Platinum compounds in the treatment of advanced breast cancer. [11899413] Clin Breast Cancer 2(3): 190-208; discussion 209 (2001)
2009 39	Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. [19254941] Ann Oncol 20(4): 615-20 (2009)
2008 40	Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. [18480068] Ann Oncol 19(9): 1530-9 (2008)
2008 41	Recent advances in adjuvant systemic therapy for early-stage breast cancer. [18611869] Ann Oncol 19 Suppl 5(): v122-7 (2008)
2008 42	The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. [18407953] Ann Oncol 19(7): 1213-5 (2008)
2008 43	Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456775] Ann Oncol 19 Suppl 2(): ii7-10 (2008)
2008 44	Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456744] Ann Oncol 19 Suppl 2(): ii11-3 (2008)
2007 45	A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. [17264064] Ann Oncol 18(7): 1152-8 (2007)
2007 46	Lapatinib in breast cancer. [17591827] Ann Oncol 18 Suppl 6(): vi26-30 (2007)
2007 47	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. [17229773] Ann Oncol 18(6): 977-84 (2007)
2006 48	Precancerous lesions of the breast. [17018737] Ann Oncol 17 Suppl 10(): x271-3 (2006)
2005 49	Chemotherapy for metastatic breast cancer. [15923425] Ann Oncol 16 Suppl 4(): iv23-27 (2005)
2004 50	Primary chemotherapy for breast cancer: the evidence and the future. [15277254] Ann Oncol 15(8): 1161-71 (2004)
2003 51	The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. [12702519] Ann Oncol 14(5): 667-74 (2003)
1967 52	A review of 146 cases of carcinoma of the breast operated on between 1930 and 1943. [6028079] Br J Cancer 21(2): 260-9 (1967)
2005 53	A systematic review of taxane-containing regimens for metastatic breast cancer. [16052223] Br J Cancer 93(3): 293-301 (2005)
2009 54	New molecular classifications of breast cancer. [19729680] CA Cancer J Clin 59(5): 303-13 (2009)
2000 55	The diagnosis and management of ductal carcinoma in-situ of the breast. [10901741] CA Cancer J Clin 50(3): 184-200 (2000)
1998 56	Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. [9522825] CA Cancer J Clin 48(2): 108-28 (1998)
1998 57	Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. [9522824] CA Cancer J Clin 48(2): 83-107 (1998)
1997 58	Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast. [8996078] CA Cancer J Clin 47(1): 52-64 (1997)
1997 59	Tumor-related prognostic factors for breast cancer. [8996077] CA Cancer J Clin 47(1): 28-51 (1997)
1995 60	The surgical management of primary invasive breast cancer. [7656131] CA Cancer J Clin 45(5): 279-88 (1995)
1995 61	The woman at increased risk for breast cancer: evaluation and management strategies. [7656130] CA Cancer J Clin 45(5): 263-78 (1995)
1995 62	Management of ductal carcinoma in situ. [7600280] CA Cancer J Clin 45(4): 244-53 (1995)
1995 63	Primary chemotherapy in surgically resectable breast cancer. [7600279] CA Cancer J Clin 45(4): 227-43 (1995)
1995 64	Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. [7600278] CA Cancer J Clin 45(4): 199-226 (1995)
1991 65	Cancer of the breast in men. [1933534] CA Cancer J Clin 41(6): 339-54 (1991)
1991 66	The role of radiation therapy in the management of primary breast cancer. [1900035] CA Cancer J Clin 41(2): 85-96 (1991)
1991 67	The surgical management of primary breast cancer. [1900034] CA Cancer J Clin 41(2): 71-84 (1991)
2008 68	Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. [18819158] Cancer 113(9): 2385-97 (2008)
2008 69	The molecular journey from ductal carcinoma in situ to invasive breast cancer. [18383519] Cancer 112(10): 2130-42 (2008)
2007 70	Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. [17722109] Cancer 110(8): 1687-96 (2007)
2007 71	Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. [17647249] Cancer 110(6): 1187-94 (2007)
2005 72	Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? [16155942] Cancer 104(8): 1567-74 (2005)
2005 73	Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. [15770688] Cancer 103(9): 1778-84 (2005)
2005 74	Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. [15637696] Cancer 103(4): 672-9 (2005)
2004 75	The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. [15378476] Cancer 101(7): 1482-9 (2004)
2004 76	Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. [15042665] Cancer 100(7): 1337-44 (2004)
2000 77	Pathologic analysis of sentinel lymph nodes in breast carcinoma. [10699882] Cancer 88(5): 971-7 (2000)
1999 78	Understanding ductal carcinoma in situ: a step in the right direction. [10430242] Cancer 86(3): 375-7 (1999)
1999 79	Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. [10091736] Cancer 85(3): 629-39 (1999)
1998 80	Carcinoma of the breast in males: a multiinstitutional survey. [9690543] Cancer 83(3): 498-509 (1998)
1998 81	Metaplastic carcinoma of the breast: report of three cases. [9506353] Cancer 82(6): 1082-7 (1998)
1997 82	The role of histologic grading in the prognosis of patients with carcinoma of the breast: is this a neglected opportunity? [9351538] Cancer 80(9): 1708-16 (1997)
2010 83	A review of triple-negative breast cancer. [20664514] Cancer Control 17(3): 173-6 (2010)
2001 84	NCCN: Breast cancer. [11760559] Cancer Control 8(6 Suppl 2): 54-61 (2001)
1999 85	Ductal Carcinoma In Situ of the Breast. [10758556] Cancer Control 6(3): 264-271 (1999)
2008 86	Ixabepilone in metastatic breast cancer: complement or alternative to taxanes? [18980963] Clin Cancer Res 14(21): 6725-9 (2008)
1998 87	Update on endocrine therapy for breast cancer. [9533518] Clin Cancer Res 4(3): 527-34 (1998)
2009 88	International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. [19657108] J Natl Cancer Inst 101(17): 1174-81 (2009)
2008 89	Anthracyclines in the treatment of HER2-negative breast cancer. [18159066] J Natl Cancer Inst 100(1): 2-4 (2008)
2009 90	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. [19346299] Oncologist 14(4): 320-68 (2009)
2008 91	FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. [18849320] Oncologist 13(10): 1114-9 (2008)
2008 92	Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. [18586917] Oncologist 13(6): 620-30 (2008)
2008 93	Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. [18515736] Oncologist 13(5): 515-25 (2008)
2007 94	Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. [18055847] Oncologist 12(11): 1276-87 (2007)
2007 95	Steroid sulfatase: a new target for the endocrine therapy of breast cancer. [17470679] Oncologist 12(4): 370-4 (2007)
2007 96	BRCA1, a potential predictive biomarker in the treatment of breast cancer. [17296808] Oncologist 12(2): 142-50 (2007)
2006 97	Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. [16880231] Oncologist 11(7): 718-31 (2006)
2006 98	Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. [16880230] Oncologist 11(7): 704-17 (2006)
2006 99	Aromatase inhibitors in breast cancer: an overview. [16794235] Oncologist 11(6): 553-62 (2006)
2006 100	Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. [16794234] Oncologist 11(6): 541-52 (2006)
2006 101	Benign breast diseases: classification, diagnosis, and management. [16720843] Oncologist 11(5): 435-49 (2006)
2006 102	Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. [16971734] Oncologist 11 Suppl 1(): 4-12 (2006)
2005 103	A review of the diagnosis and management of male breast cancer. [16079314] Oncologist 10(7): 471-9 (2005)
2004 104	Recognition and management of hereditary breast cancer syndromes. [14755011] Oncologist 9(1): 13-24 (2004)
2003 105	Update on the management of inflammatory breast cancer. [12697939] Oncologist 8(2): 141-8 (2003)
1977 106	Comparative effects of a series of prolactin inhibitors, 17beta-estradiol and 2alpha-methyldihydrotestosterone propionate, on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. [409489] Cancer Res 37(11): 3932-8 (1977)
2010 107	Histological types of breast cancer: how special are they? [20452298] Mol Oncol 4(3): 192-208 (2010)
2005 108	Aromatase inhibitors in the treatment of breast cancer. [15814851] Endocr Rev 26(3): 331-45 (2005)
2008 109	HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. [18480007] Am J Clin Pathol 129(6): 907-11 (2008)
2008 110	HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. [18208807] Am J Clin Pathol 129(2): 263-73 (2008)
2007 111	Breast cancer: origins and evolution. [17975657] J Clin Invest 117(11): 3155-63 (2007)
2008 112	Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. [18687797] J Mol Diagn 10(5): 383-95 (2008)
2007 113	A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. [17803883] Mayo Clin Proc 82(9): 1131-40 (2007)
2007 114	A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. [17673070] Mayo Clin Proc 82(8): 999-1012 (2007)
2008 115	Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients. [19020230] AJR Am J Roentgenol 191(6): 1631-9 (2008)
2008 116	Spectrum of papillary lesions of the breast: clinical, imaging, and pathologic correlation. [18716096] AJR Am J Roentgenol 191(3): 700-7 (2008)
2001 117	Radioguided sentinel lymph node biopsy in breast cancer surgery. [11483681] J Nucl Med 42(8): 1198-215 (2001)
2009 118	From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation. [19448124] Radiographics 29(3): 907-31 (2009)
2009 119	Nipple-areolar complex: normal anatomy and benign and malignant processes. [19325062] Radiographics 29(2): 509-23 (2009)
2008 120	Rare breast lesions: correlation of imaging and histologic features with WHO classification. [18794315] Radiographics 28(5): 1399-414 (2008)
2007 121	Common and unusual diseases of the nipple-areolar complex. [18180236] Radiographics 27 Suppl 1(): S65-77 (2007)
2007 122	Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation. [18180235] Radiographics 27 Suppl 1(): S53-64 (2007)
2007 123	Breast lesions incidentally detected with CT: what the general radiologist needs to know. [18180233] Radiographics 27 Suppl 1(): S37-51 (2007)
2007 124	In vivo proton MR spectroscopy of the breast. [18180231] Radiographics 27 Suppl 1(): S253-66 (2007)
2007 125	Proton (1H) MR spectroscopy of the breast. [18180230] Radiographics 27 Suppl 1(): S241-52 (2007)
2007 126	FDG PET, PET/CT, and breast cancer imaging. [18180228] Radiographics 27 Suppl 1(): S215-29 (2007)
2007 127	FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. [18180227] Radiographics 27 Suppl 1(): S197-213 (2007)
2007 128	Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation. [18180225] Radiographics 27 Suppl 1(): S165-82 (2007)
2006 129	Imaging characteristics of malignant lesions of the male breast. [16844928] Radiographics 26(4): 993-1006 (2006)
2004 130	Thoracic manifestations of breast cancer and its therapy. [15371608] Radiographics 24(5): 1269-85 (2004)
2004 131	Normal and abnormal US findings at the mastectomy site. [15026586] Radiographics 24(2): 357-65 (2004)
2003 132	Missed breast carcinoma: pitfalls and pearls. [12853663] Radiographics 23(4): 881-95 (2003)
2002 133	Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. [11796893] Radiographics 22(1): 5-17 (2002)
1998 134	High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer. [9672975] Radiographics 18(4): 903-12 (1998)
1996 135	Lessons from mammographic-histopathologic correlation of large-core needle breast biopsy. [8888394] Radiographics 16(5): 1111-30 (1996)
1990 136	Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer. [2217975] Radiographics 10(5): 857-70 (1990)
2010 137	US of breast masses categorized as BI-RADS 3, 4, and 5: pictorial review of factors influencing clinical management. [20833845] Radiographics 30(5): 1199-213 (2010)
2010 138	Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images. [20228333] Radiographics 30(2): 533-48 (2010)
1999 139	Unusual breast lesions: radiologic-pathologic correlation. [10517440] Radiographics 19 Spec No(-): S11-26; quiz S260 (1999)
2007 140	Granular cell tumour of the breast: MRI findings and review of the literature. [17940129] Br J Radiol 80(960): 970-4 (2007)
2007 141	Mammary angiosarcomas: imaging findings in 24 patients. [17325063] Radiology 242(3): 725-34 (2007)
2007 142	Unusual breast cancers: useful clues to expanding the differential diagnosis. [17325062] Radiology 242(3): 683-94 (2007)
2006 143	Phyllodes tumor of the breast: correlation between MR findings and histologic grade. [17032912] Radiology 241(3): 702-9 (2006)
2002 144	Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. [12034956] Radiology 223(3): 829-38 (2002)
2001 145	MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. [11425968] Radiology 220(1): 13-30 (2001)
2000 146	Focal fibrosis of the breast: imaging characteristics and histopathologic correlation. [10887257] Radiology 216(1): 255-9 (2000)
1999 147	Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer. [10352613] Radiology 211(3): 835-44 (1999)
1983 148	Ultrasound, x-ray mammography, and histopathology of cystosarcoma phylloides. [6294737] Radiology 146(2): 481-6 (1983)
2010 149	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555111] Ann Oncol 21 Suppl 5(-): v9-14 (2010)
2010 150	BRCA in breast cancer: ESMO Clinical Practice Guidelines. [20555082] Ann Oncol 21 Suppl 5(-): v20-2 (2010)
2010 151	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555067] Ann Oncol 21 Suppl 5(-): v15-9 (2010)
2004 152	Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. [15477297] Ann Oncol 15 Suppl 4(-): iv133-8 (2004)
2010 153	Treatment of HER2-overexpressing breast cancer. [20943641] Ann Oncol 21 Suppl 7(-): vii36-40 (2010)
2010 154	Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? [20943632] Ann Oncol 21 Suppl 7(-): vii30-5 (2010)
2010 155	Genetic counselling for hereditary predisposition to ovarian and breast cancer. [20943638] Ann Oncol 21 Suppl 7(-): vii334-8 (2010)
2010 156	What can the pathologist offer for optimal treatment choice? [20943626] Ann Oncol 21 Suppl 7(-): vii27-9 (2010)
2010 157	Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse. [20943601] Ann Oncol 21 Suppl 7(-): vii103-6 (2010)
2010 158	Benefits and adverse effects of endocrine therapy. [20943602] Ann Oncol 21 Suppl 7(-): vii107-11 (2010)
2010 159	Chemotherapy with or without trastuzumab. [20943603] Ann Oncol 21 Suppl 7(-): vii112-9 (2010)
2007 160	Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [17491064] Ann Oncol 18 Suppl 2(-): ii9-11 (2007)
2007 161	The state of HER-2 status. [17488732] Ann Oncol 18(5): 813-5 (2007)
2009 162	BRCA in breast cancer: ESMO clinical recommendations. [19454451] Ann Oncol 20 Suppl 4(-): 19-20 (2009)
2009 163	Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454439] Ann Oncol 20 Suppl 4(-): 15-8 (2009)
2009 164	Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454421] Ann Oncol 20 Suppl 4(-): 10-4 (2009)
2009 165	Breast carcinoma--rare types: review of the literature. [19602565] Ann Oncol 20(11): 1763-70 (2009)
2010 166	Histological, molecular and functional subtypes of breast cancers. [21057215] Cancer Biol Ther 10(10): 955-60 (2010)
2007 167	MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. [17786032] Cancer Biol Ther 6(9): 1355-7 (2007)
2010 168	Cystic masses of the breast. [20093563] AJR Am J Roentgenol 194(2): W122-33 (2010)
2008 169	Angiosarcoma of the breast. [18212243] AJR Am J Roentgenol 190(2): 533-8 (2008)
2010 170	Cystic breast masses and the ACRIN 6666 experience. [20868895] Radiol Clin North Am 48(5): 931-87 (2010)
2010 171	Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation. [21071382] Radiographics 30(6): 1673-87 (2010)
2010 172	Can MR Imaging contribute in characterizing well-circumscribed breast carcinomas? [21071383] Radiographics 30(6): 1689-702 (2010)
2009 173	Emerging technologies for assessing HER2 amplification. [19762531] Am J Clin Pathol 132(4): 539-48 (2009)
2011 174	Genomic testing and therapies for breast cancer in clinical practice. [21711068] Am J Manag Care 17(5 Spec No): e174-81 (2011)
2011 175	US insurance program's experience with a multigene assay for early-stage breast cancer. [21711071] Am J Manag Care 17(5 Spec No): e194-202 (2011)
2006 176	Medical treatment of early breast cancer. I: adjuvant treatment. [16399737] BMJ 332(7532): 34-7 (2006)
2006 177	Medical treatment of early breast cancer. IV: neoadjuvant treatment. [16439402] BMJ 332(7535): 223-4 (2006)
2006 178	Medical treatment of early breast cancer. III: chemotherapy. [16424494] BMJ 332(7534): 161-2 (2006)
2008 179	Gynaecomastia and breast cancer in men. [18369226] BMJ 336(7646): 709-13 (2008)
2009 180	ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. [19527773] Biochim Biophys Acta 1796(2): 162-75 (2009)
2008 181	Overview of breast cancer staging and surgical treatment options. [18457192] Cleve Clin J Med 75 Suppl 1(-): S10-6 (2008)
2008 182	Trends in breast cancer screening and diagnosis. [18457191] Cleve Clin J Med 75 Suppl 1(-): S2-9 (2008)
2006 183	The basal phenotype of BRCA1-related breast cancer: past, present and future. [16687925] Cell Cycle 5(9): 963-7 (2006)
2010 184	The Met receptor tyrosine kinase and basal breast cancer. [20237428] Cell Cycle 9(6): 1043-50 (2010)
2010 185	Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. [20511486] Mayo Clin Proc 85(6): 560-6; quiz 566 (2010)
2009 186	Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. [19075184] Endocr Rev 30(1): 51-74 (2009)
2011 187	Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. [22069477] PLoS One 6(11): e26946 (2011)
2010 188	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. [20858840] Clin Cancer Res 16(19): 4702-10 (2010)
2010 189	Metformin: a therapeutic opportunity in breast cancer. [20215559] Clin Cancer Res 16(6): 1695-700 (2010)
2008 190	Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. [18281527] Clin Cancer Res 14(4): 961-70 (2008)
2010 191	Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. [20421264] Oncologist 15(5): 457-65 (2010)
2010 192	Review of the clinical studies using the 21-gene assay. [20421266] Oncologist 15(5): 447-56 (2010)
2010 193	Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. [20080863] Oncologist 15(1): 26-36 (2010)
2010 194	Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. [20200040] Oncologist 15(3): 216-35 (2010)
2009 195	HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. [19684074] Oncologist 14(8): 760-8 (2009)
2008 196	Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. [18448551] Oncologist 13(4): 373-81 (2008)
2009 197	Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. [19887469] Oncologist 14(11): 1061-9 (2009)
2010 198	Primary systemic chemotherapy for inflammatory breast cancer. [20503414] Cancer 116(11 Suppl): 2821-8 (2010)
2010 199	Inflammatory breast cancer--The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. [20503413] Cancer 116(11 Suppl): 2815-20 (2010)
2010 200	Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. [20503411] Cancer 116(11 Suppl): 2794-805 (2010)
2010 201	Gene expression profiling of inflammatory breast cancer. [20503410] Cancer 116(11 Suppl): 2783-93 (2010)
2010 202	Targeted therapy in inflammatory breast cancer. [20503407] Cancer 116(11 Suppl): 2758-9 (2010)
2010 203	Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. [20503405] Cancer 116(11 Suppl): 2748-54 (2010)
2010 204	Potential impact of tumor registry rule changes for recording inflammatory breast cancer. [20503404] Cancer 116(11 Suppl): 2745-7 (2010)
2006 205	Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. [16770784] Cancer 107(2): 221-31 (2006)
2011 206	Adjuvant therapy for women over age 65 with breast cancer. [21691560] Dtsch Arztebl Int 108(21): 365-71 (2011)
2010 207	A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. [21044553] Health Technol Assess 14(50): 1-103 (2010)
2009 208	Lapatinib for the treatment of HER2-overexpressing breast cancer. [19846022] Health Technol Assess 13 Suppl 3(-): 1-6 (2009)
2009 209	Male breast cancer: experience from a Malaysian tertiary centre. [19495524] Singapore Med J 50(5): 519-21 (2009)
2011 210	Diagnosis and local management of breast cancer: part I. [21823890] Future Oncol 7(8): 955-7 (2011)
2011 211	Diagnosis and local management of breast cancer: part II. [21823891] Future Oncol 7(8): 959-61 (2011)
2009 212	Current role of breast duct microendoscopy in malignancy. [20001790] Future Oncol 5(10): 1523-6 (2009)
2002 213	Perspectives on the chemical etiology of breast cancer. [11834470] Environ Health Perspect 110 Suppl 1(-): 119-28 (2002)
2011 214	False-negative tests in breast cancer management. [21934177] Neth J Med 69(7): 324-9 (2011)
2002 215	Anti-aromatase agents in the treatment and prevention of breast cancer. [11965225] Cancer Control 9(2 Suppl): 2-8 (2002)
2002 216	Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. [11965226] Cancer Control 9(2 Suppl): 9-15 (2002)
2002 217	The expanding role of epirubicin in the treatment of breast cancer. [11965227] Cancer Control 9(2 Suppl): 16-27 (2002)
2007 218	High-risk benign breast lesions: current strategies in management. [17914332] Cancer Control 14(4): 321-9 (2007)
2007 219	Management options after prophylactic surgeries in women with BRCA mutations: a review. [17914333] Cancer Control 14(4): 330-7 (2007)
2007 220	Breast ductal secretions: clinical features, potential uses, and possible applications. [17914335] Cancer Control 14(4): 350-9 (2007)
2005 221	Molecularly targeted therapies for breast cancer. [15855890] Cancer Control 12(2): 73-81 (2005)
2010 222	Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. [20203220] J Clin Pathol 63(3): 210-9 (2010)
2007 223	Non-operative breast pathology: columnar cell lesions. [17182657] J Clin Pathol 60(12): 1307-12 (2007)
2007 224	Non-operative breast pathology: lobular neoplasia. [17182661] J Clin Pathol 60(12): 1321-7 (2007)
2007 225	Demystifying basal-like breast carcinomas. [17496191] J Clin Pathol 60(12): 1328-32 (2007)
2007 226	Non-operative breast pathology. [18042687] J Clin Pathol 60(12): 1297-9 (2007)
2007 227	Non-operative breast pathology: apocrine lesions. [18042688] J Clin Pathol 60(12): 1313-20 (2007)
2010 228	Diagnostic evaluation of papillary lesions of the breast on core biopsy. [20473278] Mod Pathol 23(7): 1021-8 (2010)
2010 229	Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. [20436497] Mod Pathol 23 Suppl 2(-): S1-7 (2010)
2010 230	Lobular neoplasia: morphology, biological potential and management in core biopsies. [20436498] Mod Pathol 23 Suppl 2(-): S14-25 (2010)
2010 231	Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. [20436499] Mod Pathol 23 Suppl 2(-): S26-32 (2010)
2010 232	Clinical applications of breast pathology: management of in situ breast carcinomas and sentinel node biopsy issues. [20436500] Mod Pathol 23 Suppl 2(-): S33-5 (2010)
2010 233	Breast core needle biopsy: issues and controversies. [20436501] Mod Pathol 23 Suppl 2(-): S36-45 (2010)
2010 234	Pathology of hereditary breast cancer. [20436502] Mod Pathol 23 Suppl 2(-): S46-51 (2010)
2010 235	Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. [20436503] Mod Pathol 23 Suppl 2(-): S52-9 (2010)
2010 236	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. [20436504] Mod Pathol 23 Suppl 2(-): S60-4 (2010)
2010 237	Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. [20436505] Mod Pathol 23 Suppl 2(-): S8-13 (2010)
2005 238	The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. [15933754] Mod Pathol 18(10): 1305-20 (2005)
2008 239	Her2 cross talk and therapeutic resistance in breast cancer. [18508484] Front Biosci 13(-): 3906-12 (2008)
2007 240	The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. [17673939] Mol Med 13(7-8): 396-406 (2007)
2009 241	MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. [19580428] Expert Rev Mol Diagn 9(5): 423-40 (2009)
2011 242	Unraveling the complexity of basal-like breast cancer. [21876228] Oncotarget 2(8): 588-9 (2011)
2011 243	A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. [21709316] Oncotarget 2(7): 529-37 (2011)
2011 244	Elevated PI3K signaling drives multiple breast cancer subtypes. [21646685] Oncotarget 2(6): 435-47 (2011)
2002 245	Stromal effects on mammary gland development and breast cancer. [12004111] Science 296(5570): 1046-9 (2002)
2009 246	The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions. [19372493] J Nucl Med 50(5): 738-48 (2009)
2009 247	Response to therapy in breast cancer. [19380410] J Nucl Med 50 Suppl 1(-): 55S-63S (2009)
2010 248	The emerging role of Krüppel-like factors in endocrine-responsive cancers of female reproductive tissues. [19833720] J Endocrinol 204(3): 223-31 (2010)
2002 249	Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. [11914182] Endocr Relat Cancer 9(1): 45-59 (2002)
2002 250	The development and clinical use of trastuzumab (Herceptin). [12121832] Endocr Relat Cancer 9(2): 75-85 (2002)
2011 251	Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. [21613412] Endocr Relat Cancer 18(4): C19-24 (2011)
2011 252	A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. [21502311] Endocr Relat Cancer 18(3): R79-89 (2011)
2011 253	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. [21342044] Expert Rev Anticancer Ther 11(2): 263-75 (2011)
2011 254	Targeting the leptin receptor: a potential new mode of treatment for breast cancer. [21916566] Expert Rev Anticancer Ther 11(8): 1147-50 (2011)
2008 255	Rational targeting of Notch signaling in breast cancer. [18699758] Expert Rev Anticancer Ther 8(8): 1197-202 (2008)
2010 256	Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment. [20131988] Expert Rev Anticancer Ther 10(2): 129-32 (2010)
2010 257	Tumour suppressor function of MDA-7/IL-24 in human breast cancer. [20735832] Cancer Cell Int 10(): 29 (2010)
2012 258	Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo. [22640485] J Exp Clin Cancer Res 31(1): 51 (2012)
2010 259	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. [20520800] PLoS Med 7(5): e1000279 (2010)
2011 260	Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. [21693041] Reprod Biol Endocrinol 9(-): 91 (2011)
2010 261	Estrogen and xenoestrogens in breast cancer. [19933552] Toxicol Pathol 38(1): 110-22 (2010)
2007 262	New biomarkers in breast cancer: microRNAs and leptins--where are we now? [20477455] Biomark Med 1(1): 9-11 (2007)
2008 263	Tpl-2/Cot and COX-2 in breast cancer. [18795070] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152(1): 21-5 (2008)
2002 264	Progesterone receptors--animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. [12473170] Breast Cancer Res 4(6): 240-3 (2002)
2002 265	Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies. [12473171] Breast Cancer Res 4(6): 244-8 (2002)
2002 266	Actions of bisphosphonates in animal models of breast cancer. [11879558] Breast Cancer Res 4(1): 35-41 (2002)
2002 267	Progesterone receptors - animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. [12223121] Breast Cancer Res 4(5): 182-6 (2002)
2002 268	The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. [12223124] Breast Cancer Res 4(5): 197-201 (2002)
2002 269	Direct effects of bisphosphonates on breast cancer cells. [11879555] Breast Cancer Res 4(1): 18-23 (2002)
2011 270	Therapeutic targets for bone metastases in breast cancer. [21586099] Breast Cancer Res 13(2): 207 (2011)
2011 271	Functional magnetic resonance: biomarkers of response in breast cancer. [21392409] Breast Cancer Res 13(1): 204 (2011)
2011 272	Gene signatures of breast cancer progression and metastasis. [21345283] Breast Cancer Res 13(1): 201 (2011)
2004 273	Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. [14680484] Breast Cancer Res 6(1): 39-52 (2004)
2003 274	The diagnosis and management of pre-invasive breast disease--current challenges, future hopes. [12927033] Breast Cancer Res 5(5): 248-9 (2003)
2003 275	The diagnosis and management of pre-invasive breast disease: radiological diagnosis. [12927034] Breast Cancer Res 5(5): 250-3 (2003)
2003 276	The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. [12927035] Breast Cancer Res 5(5): 254-7 (2003)
2003 277	The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. [12927036] Breast Cancer Res 5(5): 258-62 (2003)
2003 278	The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance. [12927037] Breast Cancer Res 5(5): 263-8 (2003)
2003 279	The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications. [12927038] Breast Cancer Res 5(5): 269 (2003)
2003 280	Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. [12631389] Breast Cancer Res 5(2): 101-6 (2003)
2010 281	Breast cancer metastasis to the bone: mechanisms of bone loss. [21176175] Breast Cancer Res 12(6): 215 (2010)
2010 282	Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. [20594364] Breast Cancer Res 12(3): 206 (2010)
2010 283	Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. [21050423] Breast Cancer Res 12 Suppl 2(-): S2 (2010)
2010 284	Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. [20398329] Breast Cancer Res 12(2): 202 (2010)
2010 285	Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. [20459590] Breast Cancer Res 12(2): 203 (2010)
2010 286	Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors. [20497549] Breast Cancer Res 12(3): R29 (2010)
2010 287	Tumour-associated carbohydrate antigens in breast cancer. [20550729] Breast Cancer Res 12(3): 204 (2010)
2009 288	Epithelial to mesenchymal transition and breast cancer. [19909494] Breast Cancer Res 11(6): 213 (2009)
2008 289	PGRMC1: a new biomarker for the estrogen receptor in breast cancer. [19090968] Breast Cancer Res 10(6): 113 (2008)
2008 290	Fatal attraction: why breast cancer cells home to bone. [18226190] Breast Cancer Res 10(1): 101 (2008)
2009 291	Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells. [19996302] Mol Cancer Res 7(12): 2000-10 (2009)
2011 292	High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. [22178934] Cell Physiol Biochem 28(5): 813-22 (2011)
2012 293	Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor negative breast cancer. [22807578] Mol Cancer Ther (): (2012)
2008 294	The role of TRPV6 in breast carcinogenesis. [18245667] Mol Cancer Ther 7(2): 271-9 (2008)
2007 295	Brain metastases from breast cancer: management approach. [18079579] J Cancer Res Ther 3(3): 157-65 (2007)
2010 296	Advantages of Ductal Echography (DE) over conventional breast investigation in the diagnosis of breast malignancies. [21165452] Med Ultrason 12(1): 32-42 (2010)
2011 297	Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. [21655158] Curr Oncol 18(3): 119-25 (2011)
2011 298	Triple-negative breast cancers: an updated review on treatment options. [21874107] Curr Oncol 18(4): e173-9 (2011)
2011 299	Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. [21874117] Curr Oncol 18(4): 180-90 (2011)
2011 300	A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. [21874118] Curr Oncol 18(4): 191-6 (2011)
2010 301	Endocrine therapy for male breast cancer: rates of toxicity and adherence. [20975874] Curr Oncol 17(5): 17-21 (2010)
2008 302	A primer of bone metastases management in breast cancer patients. [18231649] Curr Oncol 15(Suppl 1): S50-7 (2008)
2010 303	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. [20404251] J Clin Oncol 28(16): 2784-95 (2010)
2009 304	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. [19470930] J Clin Oncol 27(19): 3235-58 (2009)
2010 305	Inflammatory breast cancer: the disease, the biology, the treatment. [20959401] CA Cancer J Clin 60(6): 351-75 (2010)
2008 306	The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography. [18270336] J Natl Cancer Inst 100(4): 228-9 (2008)
2011 307	Diffuse infiltrative lesion of the breast: clinical and radiologic features. [21228947] Korean J Radiol 12(1): 113-21 (2011)
2007 308	The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. [17892469] Int J Clin Pract 61(12): 2051-63 (2007)
2010 309	Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. [20101445] J Mammary Gland Biol Neoplasia 15(1): 35-47 (2010)
2010 310	Breast cancer epigenetics: from DNA methylation to microRNAs. [20101446] J Mammary Gland Biol Neoplasia 15(1): 5-17 (2010)
2007 311	Metastasis suppressors and their roles in breast carcinoma. [17587154] J Mammary Gland Biol Neoplasia 12(2-3): 175-90 (2007)
2009 312	Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? [19350209] J Mammary Gland Biol Neoplasia 14(2): 145-57 (2009)
2009 313	Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. [19396528] J Mammary Gland Biol Neoplasia 14(2): 131-44 (2009)
2008 314	The contribution of growth hormone to mammary neoplasia. [18253708] J Mammary Gland Biol Neoplasia 13(1): 131-45 (2008)
2011 315	Bevacizumab in metastatic breast cancer: when may it be used? [21789158] Ther Adv Med Oncol 3(2): 85-93 (2011)
2008 316	Arzoxifene: the evidence for its development in the management of breast cancer. [21221190] Core Evid 2(4): 251-8 (2008)
2009 317	Non-epithelial malignancies and metastatic tumours of the breast. [19568446] Ulster Med J 78(2): 105-12 (2009)
2002 318	Antiaromatase agents: evolving role in adjuvant therapy. [12020394] Clin Breast Cancer 3(1): 33-42 (2002)
2008 319	Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. [19073502] Clin Breast Cancer 8(6): 487-92 (2008)
2009 320	Enhancing the efficacy of hormonal agents with selected targeted agents. [19561004] Clin Breast Cancer 9 Suppl 1(-): S28-36 (2009)
2009 321	A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. [19561006] Clin Breast Cancer 9 Suppl 1(-): S6-S17 (2009)
2009 322	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. [19596646] Clin Breast Cancer 9 Suppl 2(-): S73-81 (2009)
2009 323	Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? [19561003] Clin Breast Cancer 9 Suppl 1(-): S18-27 (2009)
2008 324	Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. [18621608] Clin Breast Cancer 8(2): 124-33 (2008)
2009 325	Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. [20360896] Int J Gen Med 2(-): 129-40 (2009)
2011 326	Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. [21552384] J Cancer 2(-): 232-61 (2011)
2010 327	American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. [21037871] J Oncol Pract 6(4): 195-7 (2010)
2010 328	Breast cancer as an infectious disease. [20088725] Womens Health (Lond Engl) 6(1): 5-8 (2010)
2010 329	A rare tumour of the breast: carcinosarcoma. [21811528] J Clin Med Res 2(2): 96-8 (2010)
2011 330	Sonographic findings of additional malignant lesions in breast carcinoma seen by second look ultrasound. [21966631] J Clin Imaging Sci 1(-): 34 (2011)
2009 331	The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. [19418218] Breast Cancer Res Treat 116(2): 225-37 (2009)
2008 332	An overview of prognostic factors for long-term survivors of breast cancer. [17377838] Breast Cancer Res Treat 107(3): 309-30 (2008)
2010 333	Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. [20886213] Cancer Chemother Pharmacol 66(6): 1005-12 (2010)
2010 334	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. [20524868] Arch Pathol Lab Med 134(6): 907-22 (2010)
2011 335	Pathology of hereditary breast cancer. [21336636] Cell Oncol (Dordr) 34(2): 71-88 (2011)
2011 336	Myofibroblastoma of the breast: Case report and literature review. [22096693] Int J Surg Case Rep 2(6): 93-6 (2011)
2011 337	Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. [22109790] J Community Genet 2(2): 53-69 (2011)
2004 338	DNA double strand break repair and its association with inherited predispositions to breast cancer. [20233482] Hered Cancer Clin Pract 2(1): 37-43 (2004)
2011 339	The 70-gene prognostic signature for korean breast cancer patients. [21847392] J Breast Cancer 14(1): 33-8 (2011)
2008 340	Epigenetic gene silencing in the Wnt pathway in breast cancer. [18398311] Epigenetics 3(2): 59-63 (2008)
2008 341	Matrix-producing mammary carcinoma: a rare breast tumor. [18603703] Indian J Pathol Microbiol 51(2): 263-4 (2008)
2008 342	Progesterone receptor isoform functions in normal breast development and breast cancer. [18197783] Crit Rev Eukaryot Gene Expr 18(1): 11-33 (2008)
2011 343	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. [21569417] J Exp Clin Cancer Res 30(-): 54 (2011)
2008 344	ERbeta in breast cancer--onlooker, passive player, or active protector? [18501937] Steroids 73(11): 1039-51 (2008)
2011 345	Breast cancer at bone metastatic sites: recent discoveries and treatment targets. [21484191] J Cell Commun Signal 5(2): 85-99 (2011)
2010 346	Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. [21081926] Br J Cancer 103(12): 1788-93 (2010)
2011 347	Triple negative breast cancer: unmet medical needs. [21161370] Breast Cancer Res Treat 125(3): 627-36 (2011)
2010 348	Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. [20700648] Breast Cancer Res Treat 124(3): 863-73 (2010)
2010 349	Strut-adjusted volume implant: a targeted radiation treatment in breast cancer. [21142853] Future Oncol 6(12): 1813-6 (2010)
2010 350	Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. [21161341] J Mammary Gland Biol Neoplasia 15(4): 389-97 (2010)
2010 351	EGFR signaling in breast cancer: bad to the bone. [20813200] Semin Cell Dev Biol 21(9): 951-60 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Mammary gland (Neoplasia).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Mammary gland (Neoplasia).php on line 92